State initiatives to control medication costs - Can transparency legislation help?

New England Journal of Medicine

Volumn 374, Issue 24, 2016, Pages 2301-2304

  Sarpatwari, Ameet ^a   Avorn, Jerry ^a   Kesselheim, Aaron S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; DRUG COST; DRUG DEVELOPMENT; DRUG LEGISLATION; DRUG RESEARCH; INFORMATION; MEDICAID; MEDICARE; POLITICS; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY; UNITED STATES; DRUG INDUSTRY; ECONOMICS; GOVERNMENT; GOVERNMENT REGULATION; HUMAN; LEGISLATION AND JURISPRUDENCE;

PRESCRIPTION DRUG;

COST CONTROL; DRUG COSTS; DRUG DISCOVERY; DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PRESCRIPTION DRUGS; STATE GOVERNMENT; UNITED STATES;

EID: 84974799165     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1605100     Document Type: Short Survey

References (5)

1. Medicine use and spending in the U.S. - a review of 2015 and outlook to 2020. IMS Institute for Healthcare Informatics, 2016 (https://www.imshealth.com/en/thought-leadership/ims-institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2015-and-outlook-to-2020).
2. Barlas S. States try to control Medicaid pharmaceutical costs: numerous, diverse cost pressures force myriad reform efforts. P T 2015;40:260-2.
3. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-23.
4. Avorn J. The $2.6 billion pill - methodologic and policy considerations. N Engl J Med 2015;372:1877-9.
5. Anderson R. Pharmaceutical industry gets high on fat profits. BBC News. November 6, 2014 (http://www.bbc.com/news/business-28212223).